Rights to antibody drug by China’s Keymed change hands in Gilead acquisition of Ouro

US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal worth up to US$2.18 billion. Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines. Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion...


5 d.
Technology
ID: -7610359089132624760


Similar News expand_more


Technology
Science
Technology
Science
Technology
Science
Technology
Economics
Crime
Technology
Technology
Technology
Science
Technology
Science
Technology
Science
Technology
Military
Crime
Technology
Technology
Technology
Technology
Science
Economics
Technology
Science
Technology
Technology
Politics
Science
Technology
Politics
Science
Politics
Politics
Politics
Technology
Economics
Technology
Science
Technology
Science
Military
Technology
Technology
Science
Crime
Popular countries based on strong economic and political relations

Add Watch Country

arrow_drop_down